| Zacks Company Profile for Shionogi & Co., Ltd. Unsponsored ADR (SGIOY : OTC) |
|
|
| |
| • Company Description |
| Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.
Number of Employees: 4,959 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $8.43 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 76,836 shares |
| Shares Outstanding: 1,701.38 (millions) |
| Market Capitalization: $14,342.63 (millions) |
| Beta: 0.21 |
| 52 Week High: $8.99 |
| 52 Week Low: $6.53 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-1.29% |
-4.98% |
| 12 Week |
1.81% |
-14.36% |
| Year To Date |
21.12% |
13.43% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
1-8 DOSHOMACHI 3-CHOME
-
OSAKA,M0 541-0045
JPN |
ph: 816-620-2216
fax: - |
None |
http://www.shionogi.com |
|
|
| |
| • General Corporate Information |
Officers
IsaoTeshirogi - President and CEO
Keiichi Ando - Chairperson
Takuko Sawada - Director and Vice Chairperson of the Board
Hiroshi Ozaki - Director
Fumi Takatsuki - Director
|
|
Peer Information
Shionogi & Co., Ltd. Unsponsored ADR (GSAC)
Shionogi & Co., Ltd. Unsponsored ADR (CASI)
Shionogi & Co., Ltd. Unsponsored ADR (ALCD.)
Shionogi & Co., Ltd. Unsponsored ADR (OMNN)
Shionogi & Co., Ltd. Unsponsored ADR (CGPI.)
Shionogi & Co., Ltd. Unsponsored ADR (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 824667109
SIC: 8880
|
|
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
|
|
Share - Related Items
Shares Outstanding: 1,701.38
Most Recent Split Date: 10.00 (1.50:1)
Beta: 0.21
Market Capitalization: $14,342.63 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 1.82% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.15 |
| Current Fiscal Year EPS Consensus Estimate: $0.71 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 6.09% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/04/25 |
|
|
|
| |
